Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension

References

• HumbertMSibtonOChaoutAPulmonary arterial hypertension in France: Results from a national registryAm J Respir Crit Care Med20061731023102616456139
   PubMed Web of Science ®Google Scholar
• ButrousGGhofraniHAGrimmingerFPulmonary vascular diseases in the developing worldCirculation20081181758176618936338
   PubMed Web of Science ®Google Scholar
• D’AlonzoGEBarstRJAyresSMSurvival in patients with primary pulmonary hypertension: results from a national prospective registryAnn Intern Med19911153433491863023
   PubMed Web of Science ®Google Scholar
• McLaughlinVVSibtonOBadeschDBSurvival with first-line bosentan in patients with primary pulmonary hypertensionEur Respir J200525244249 Erratum in Eur Respir J. 2005;25:94215684287
   PubMed Web of Science ®Google Scholar
• MichelakisEDWilkinsMRRabinovitchMEmerging concepts and translational priorities in pulmonary arterial hypertensionCirculation20081181486149518824655
   PubMed Web of Science ®Google Scholar
• ArcherSLMichelakisEDPhosphodiesterase type 5 Inhibitors for pulmonary arterial hypertensionN Engl J Med20093611864186119890129
   PubMed Web of Science ®Google Scholar
• GoldsteinILueTFPadma-NathanHOral sildenafil in the treatment of erectile dysfunctionN Engl J Med1998338139714049580646
   PubMed Web of Science ®Google Scholar
• GalieNSildenafil citrate therapy for pulmonary arterial hypertensionN Engl J Med20053532148215716291984
   PubMed Web of Science ®Google Scholar
• LucasKAPitariGMKazerounianSGuanyl cyclases and signaling by cyclic GMPPharmacol Rev20005237541310977868
   PubMed Web of Science ®Google Scholar
• MoncadaSPalmerRMHiggsEANitric oxide: physiology, pathophysiology and pharmacologyPharmacol Rev1991431091421852778
   PubMed Web of Science ®Google Scholar
• TantiniBManesAFiumanaEAntiproliferative effect of sildenafil on human pulmonary artery smooth muscle cellsBasic Res Cardiol200510013113815739122
   PubMed Web of Science ®Google Scholar
• GirgisREChampionHCDietteGBDecreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapyAm J Respir Crit Care Med200517235235715879413
   PubMed Web of Science ®Google Scholar
• BeallCMLaskowskiDStrohlKPPulmonary nitric oxide in mountain dwellersNature200141441141211719794
   PubMed Web of Science ®Google Scholar
• WangCWangJZhaoLSildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entryJ Pharmacol Sci2008108717818818482
   PubMed Web of Science ®Google Scholar
• FrancisSHCorbinJDSildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunctionExpert Opin Drug Metab Toxicol2005128329316922643
   PubMedGoogle Scholar
• WhartonJAntiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cellsAm J Respir Crit Care Med200517210511315817798
   PubMed Web of Science ®Google Scholar
• CorbinJDBeasleyABlountMAHigh lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitorsBiochem Biophys Res Commun200533493093816023993
   PubMed Web of Science ®Google Scholar
• HaynesJKithasPATaylorAESelective inhibition of cGMPinhibitable cAMP phosphodiesterase decreases pulmonary vasore-activityAm J Physiol1991261H487H4921652213
   PubMed Web of Science ®Google Scholar
• ZhaoLSildenafil inhibits hypoxia-induced pulmonary hypertensionCirculation200110442442911468204
   PubMed Web of Science ®Google Scholar
• KosmickiMALong-term use of short and long-acting nitrates in stable angina pectorisCurr Clin Pharmacol2009413214119442078
   PubMedGoogle Scholar
• AbdollahiMFooladianFEmaniBProtection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and salivaHum Exp Toxicol20032258759214686481
   PubMed Web of Science ®Google Scholar
• PerkHArmaganANazirogluMSildenafil citrate as a phosphodiesterase inhibitor has an antioxidant effect in the blood of menJ Clin Pharm Ther20083363564019138241
   PubMed Web of Science ®Google Scholar
• NagendranJArcherSLSolimanDPhosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractilityCirculation200711623824817606845
   PubMed Web of Science ®Google Scholar
• MichelakisETymchakWLienDOral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxideCirculation20021052398240312021227
   PubMed Web of Science ®Google Scholar
• LeporeJJMarooABigatelloLMHemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxideChest20051271647165315888841
   PubMed Web of Science ®Google Scholar
• DillerGPvan EijlSOkonkoDoCirculation endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertensionCirculation20081173020303018519847
   PubMed Web of Science ®Google Scholar
• SchermulyRTPullamsettiSSKwapiszewskaGPhosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapyCirculation20071152331233917438150
   PubMed Web of Science ®Google Scholar
• NicholsDJMuirheadGJHarnessJAPharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionalityBr J Clin Pharmacol200253Suppl 15S12S11879254
   PubMed Web of Science ®Google Scholar
• MuirheadGJWilnerKColburnWThe effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafilBr J Clin Pharmacol200253Suppl 121S30S11879256
   PubMed Web of Science ®Google Scholar
• Revatio.com [Home page on the internet] Updated 11/2009. http://www.revatio.com/intermediateLaunch.aspxAccessed 12/27/2009. Accessed Dec 2009
   Google Scholar
• HuangSHermesDeSantisEvelynRTreatment of pulmonary arterial hypertension in pregnancyAm J Health Syst Pharm2007641922192617823103
   PubMed Web of Science ®Google Scholar
• WebbDJFreestoneSAllenMJSildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonistAm J Cardiol19998321C28C10073779
   PubMed Web of Science ®Google Scholar
• WebbDJMuirheadGJWulffMSildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable anginaJ Am Coll Cardiol200036253110898408
   PubMed Web of Science ®Google Scholar
• JacksonGBenjaminNJacksonNEffects of sildenafil citrate on human hemodynamicsAm J Cardiol19998313C20C
   PubMed Web of Science ®Google Scholar
• LatiesAMVision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to dateDrug Saf20093211819132801
   PubMed Web of Science ®Google Scholar
• PhilipARamachandaniSDorranceKSildenafil-induced thrombocytopeniaAnn Intern Med200814943743918794570
   PubMed Web of Science ®Google Scholar
• PrasadSWilkinsonJGatzoulisMASildenafil in primary pulmonary hypertensionN Engl J Med2000343134211183578
   PubMed Web of Science ®Google Scholar
• AtzAMWesselDLSildenafil ameliorates effects of inhaled nitric oxide withdrawalAnesthesiology19999130731010422958
   PubMed Web of Science ®Google Scholar
• SastryBKNarasimhanCReddyNKClinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover studyJ Am Coll Cardiol2004431149115315063421
   PubMed Web of Science ®Google Scholar
• BadeschDBHillNSBurgessGSildenafil for pulmonary arterial hypertension associated with connective tissue diseaseJ Rheumatol2007342417242217985403
   PubMed Web of Science ®Google Scholar
• MichelakisEDTymchakWNogaMLong-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertensionCirculation20031082066206914568893
   PubMed Web of Science ®Google Scholar
• McLaughlinVVArcherSLBadeschDBACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension AssociationJ Am Coll Cardiol2009531573161919389575
   PubMed Web of Science ®Google Scholar
• WilkinsMRPaulGAStrangeJWSildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) StudyAm J Respir Crit Care Med20051711292129715750042
   PubMed Web of Science ®Google Scholar
• HemmesARRobbinsIMSildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantationLiver Transpl200915151919109843
   PubMed Web of Science ®Google Scholar
• SimonneauGRubinLJGalieNAddition of sildenafil to long-term intravenous Epoprostenol therapy in patients with pulmonary arterial hypertensionAnn Intern Med200814952153018936500
   PubMed Web of Science ®Google Scholar
• GhofraniHARoseFSchermulyRTOral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertensionJ Am Coll Cardiol20034215816412849677
   PubMed Web of Science ®Google Scholar
• BurgessGHoogkamerHCollingsLMutual pharmacokinetic interactions between steady-state bosentan and sildenafilEur J Clin Pharmacol200864435018040672
   PubMed Web of Science ®Google Scholar
• GruenigEMichelakisEVachieryJLAcute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 studyJ Clin Pharmacol2009491343135219755415
   PubMed Web of Science ®Google Scholar
• SpenceRMandagereADuftonCPharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteersJ Clin Pharmacol2008481451145918832294
   PubMed Web of Science ®Google Scholar
• GannMCClarkLChumneyECCost-utility of treatment for pulmonary arterial hypertension: a Markov state-transition decision analysis modelClin Drug Investig200929635646
   Web of Science ®Google Scholar
• GalieNBundageBHGhofraniHATadalafil therapy for pulmonary arterial hypertensionCirculation20091192894290319470885
   PubMed Web of Science ®Google Scholar
• WrishkoREDingemanseJYuAPharmacokinetic interaction between tadalafil and bosentan in healthy male subjectsJ Clin Pharmacol20084861061818305126
   PubMed Web of Science ®Google Scholar
• ReichenbergerFLong-term treatment with sildenafil in chronic thromboembolic pulmonary hypertensionEur Respir J20073092292717690123
   PubMed Web of Science ®Google Scholar
• DeSantoLSMastroianniCRomanoGRole of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patientsTransplant Proc2008402015201818675118
   PubMed Web of Science ®Google Scholar
• MilmanNBurtonCMIversenMPulmonary hypertension in end stage pulmonary sarcoidosis: therapeutic effect of sildenafil?J Heart Lung Transplant20082732933418342757
   PubMed Web of Science ®Google Scholar
• HolverdaSRietemaHBogaardHJAcute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPDPulm Pharmacol Ther20082155856418342559
   PubMed Web of Science ®Google Scholar
• RichaletJPGratadourPRobachPSildenafil inhibits altitude-induced hypoxemia and pulmonary hypertensionAm J Respir Crit Care Med200517127528115516532
   PubMed Web of Science ®Google Scholar
• GhofraniHAWiedemannRRoseFSildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trialLancet200236089590012354470
   PubMed Web of Science ®Google Scholar
• FriesRShariatKvon WilmowskyHSildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapyCirculation20051122980298516275885
   PubMed Web of Science ®Google Scholar
• HoeperMMBarberaJAChannickRNDiagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertensionJ Am Coll Cardiol200954S85S9619555862
   PubMed Web of Science ®Google Scholar
• KatzSDParkerJDGlasserDBEfficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failureAm J Cardiol200595364215619391
   PubMed Web of Science ®Google Scholar
• PackerMCarverJRRodehefferRJfor the PROMISE study research groupEffect of oral milrinone on mortality in severe chronic heart failureN Engl J Med1991325146814751944425
   PubMed Web of Science ®Google Scholar
• MelenovskyVAl-HitiHKazdovaLTranspulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafilJ Am Coll Cardiol20095459560019660688
   PubMed Web of Science ®Google Scholar
• LewisGDShahRVPappagianopolasPPDeterminants of ventilator efficiency in heart failure: the role of right ventricular performance and pulmonary vascular toneCirc Heart Fail2008122723319808296
   PubMed Web of Science ®Google Scholar
• BehlingARohdeLEColomboFCEffect of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind placebo-controlled clinical trialJ Card Fail20081418919718381181
   PubMed Web of Science ®Google Scholar
• GuazziMSamajaMArenaRLong-term use of sildenafil in the therapeutic management of heart failureJ Am Coll Cardiol2007502136214418036451
   PubMed Web of Science ®Google Scholar
• StehlikJMovsesianMACombined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension patients with heart failureJ Card Fail200915313419181291
   PubMed Web of Science ®Google Scholar
• HumbertMSitbonOSimonneauGTreatment of pulmonary arterial hypertensionN Engl J Med20043511425143615459304
   PubMed Web of Science ®Google Scholar
• BarstRJPulmonary Arterial Hypertension: Diagnosis and Evidence-Based TreatmentWest Sussex, EnglandJohn Wiley & Sons2008
   Google Scholar
• McLaughlinVVMcGoonMDPulmonary arterial hypertensionCirculation20061141417143117000921
   PubMed Web of Science ®Google Scholar